Cardiovascular Clinical Trials Market
Cardiovascular Clinical Trials Market Size, Share & Trends Analysis Report by Phase (Phase I, Phase II, Phase III, and Phase IV), by Study Design (Observational, Interventional, and Expanded Access), by Indication (Coronary Artery Disease, Acute Coronary Syndrome, Pulmonary Arterial Hypertension, Ischemic Heart Disease, Stroke, Heart Failure, and Others), Forecast Period (2023-2030) Update Available - Forecast 2024-2030
Cardiovascular clinical trials market is anticipated to grow at a CAGR of 6.4% during the forecast period (2023-2030). Pivotal factors including the increasing prevalence of peripheral vascular diseases (PVDs) and coronary artery diseases (CAD). According to the World Health Organization, Cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. In addition, an academic clinical research organization united the clinical expertise and academic leadership of a premier teaching hospital with the capabilities of a full-service contract research organization. The research teams of faculty and operational experts are providing independence, scientific leadership, and collaborative approaches to look at research challenges differently. For instance, in June 2023, Duke Clinical Research Institute entered a new partnership with Novo Nordisk to fight cardiovascular disease. This partnership is driven by a motivation to produce first-in-class therapies capable of meeting the patients’ urgent medical needs.
Segmental Outlook
The global cardiovascular clinical trials market is segmented on the product, mode of delivery and end-user. Based on the phase, the market is sub-segmented into phase i, phase ii, phase iii, phase iv. Based on the study design, the market is sub-segmented into observational, interventional, and expanded access. Further, based on Indication, the market is sub-segmented into coronary artery disease, acute coronary syndrome, pulmonary arterial hypertension, ischemic heart disease, stroke, heart failure, and others. Where, the other indication includes cardiac arrhythmias. Among the study design, the interventional sub-segment is anticipated to hold a considerable share of the market, owing to the minimizing the effect of confounding, and avoid bias in allocation to exposure groups.
The Coronary Artery Disease Sub-Segment is Anticipated to Hold a Considerable Share of the Global Cardiovascular Clinical Trials Market
Among the indication, the coronary artery disease sub-segment is expected to hold a considerable share of the global cardiovascular clinical trials market. Coronary artery disease occurs when blood vessels that supply blood to the heart narrow, restricting blood flow and causing chest pain or breathing issues. The segmental growth is attributed to the increasing prevalence of coronary artery disease, rising demand for coronary artery clinical trials, and technical advancement. According to the Centers for Disease Control and Prevention (CDC), coronary heart disease is the most common type of heart disease, killing 375,476 people in 2021. About 1 in 20 adults aged 20 and older have CAD (about 5.0%). In 2021, about 2 in 10 deaths from CAD happen in adults less than 65 years old.
Regional Outlook
The global cardiovascular clinical trials market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific region is anticipated to hold a prominent share of the market across the globe, owing to the increasing prevalence of CVDs along with the changing lifestyles, rising disposable income in emerging economies.
Global Cardiovascular Clinical Trials Market Growth, by Region 2023-2030
The North America Region is Expected to Grow at a Significant CAGR in the Global Cardiovascular Clinical Trials Market
Among all regions, the North America is anticipated to grow at a considerable CAGR over the forecast period. The major factors driving the regional market growth is the increasing number of cardiovascular disorders across region, which in turn is estimated to positively impact the clinical trials in coming years. According to the American Heart Association (AHA), CVDs remains as the leading cause of demise in the US, accounted for 928,741 deaths in the year 2020. In 2020 in the US, coronary heart disease (CHD) was the leading cause (41.2%) of deaths attributable to CVD in the US, followed by stroke (17.3%), other CVD (16.8%), high blood pressure (12.9%), heart failure (9.2%), diseases of the arteries (2.6%). Additionally, owing to the presence of established contract research organizations specializing in cardiovascular clinical trials, such as global clinical trials, Caidya, ICON plc, and several others. Owing to the introduction of several innovative, ground-breaking technologies in clinical research and the provision of state-of-the-art infrastructure, numerous clinical trials for heart disorders are being performed across the region. As per Clinicaltrials.gov, as of September 2023, around 5,068 enduring cardiovascular clinical trials are registered in the US.
Market Players Outlook
The major companies serving the global cardiovascular clinical trials market include IQVIA Inc, ICON plc, Medpace, Inc., NoyMed CRO, Eli Lilly and Co., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in January 2023, AstraZeneca PLC, entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing novel treatments for resistant and uncontrolled hypertension as well as chronic kidney disease. The acquisition improved AstraZeneca’s cardiorenal pipeline by adding CinCor’s candidate drug, baxdrostat (CIN-107), an aldosterone synthase inhibitor (ASI) for blood pressure lowering in treatment-resistant hypertension.
The Report Covers
- Market value data analysis of 2022 and forecast to 2030.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global cardiovascular clinical trials market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.2. IQVIA Inc.
3.2.1. Overview
3.2.2. Financial Analysis
3.2.3. SWOT Analysis
3.2.4. Recent Developments
3.3. ICON plc
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
3.4. Medpace, Inc.
3.4.1. Overview
3.4.2. Financial Analysis
3.4.3. SWOT Analysis
3.4.4. Recent Developments
3.5. NoyMed CRO
3.5.1. Overview
3.5.2. Financial Analysis
3.5.3. SWOT Analysis
3.5.4. Recent Developments
3.6. Key Strategy Analysis
4. Market Segmentation
4.1. Global Cardiovascular Clinical Trials Market by Phase
4.1.1. Phase I
4.1.2. Phase II
4.1.3. Phase III
4.1.4. Phase IV
4.2. Global Cardiovascular Clinical Trials Market by Study Design
4.2.1. Observational
4.2.2. Interventional
4.2.3. Expanded Access
4.3. Global Cardiovascular Clinical Trials Market by Indication
4.3.1. Coronary Artery Disease
4.3.2. Acute Coronary Syndrome
4.3.3. Pulmonary Arterial Hypertension
4.3.4. Ischemic Heart Disease
4.3.5. Stroke
4.3.6. Heart Failure
4.3.7. Others (Cardiac Arrhythmias)
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Caidya
6.2. Cardialysis B.V.,
6.3. Cardiovascular Clinical Science Foundation
6.4. Clearwater Cardiovascular Consultants
6.5. Cytokinetics, Inc.
6.6. Eli Lilly and Co.
6.7. HonorHealth
6.8. Inova Health System
6.9. MCRA, LLC
6.10. PPD Inc. (Thermo Fisher Scientific Inc.
6.11. SGS SA
6.12. Syneos Health
6.13. Veeda Clinical Research Ltd.
6.14. Vial Health Technology, Inc.
6.15. Worldwide Clinical Trials
1. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY PHASE, 2022-2030 ($ MILLION)
2. GLOBAL PHASE I CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
3. GLOBAL PHASE II CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
4. GLOBAL PHASE III CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
5. GLOBAL PHASE IV CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
6. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
7. GLOBAL OBSERVATIONAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
8. GLOBAL INTERVENTIONAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
9. GLOBAL EXPANDED ACCESS CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
10. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
11. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR CORONARY ARTERY DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
12. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR ACUTE CORONARY SYNDROME MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
13. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR PULMONARY ARTERIAL HYPERTENSION MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
14. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR ISCHEMIC HEART DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
15. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR STROKE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
16. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR HEART FAILURE MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
17. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR OTHER INDICATIONMARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
18. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY REGION, 2022-2030 ($ MILLION)
19. NORTH AMERICAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
20. NORTH AMERICAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY PHASE, 2022-2030 ($ MILLION)
21. NORTH AMERICAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
22. NORTH AMERICAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
23. EUROPEAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
24. EUROPEAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY PHASE, 2022-2030 ($ MILLION)
25. EUROPEAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
26. EUROPEAN CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
27. ASIA-PACIFIC CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2022-2030 ($ MILLION)
28. ASIA-PACIFIC CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY PHASE, 2022-2030 ($ MILLION)
29. ASIA-PACIFIC CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
30. ASIA-PACIFIC CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
31. REST OF THE WORLD CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY PHASE, 2022-2030 ($ MILLION)
32. REST OF THE WORLD CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY STUDY DESIGN, 2022-2030 ($ MILLION)
33. REST OF THE WORLD CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022-2030 ($ MILLION)
1. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY PHASE, 2022 VS 2030 (%)
2. GLOBAL PHASE I CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
3. GLOBAL PHASE II CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
4. GLOBAL PHASE III CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
5. GLOBAL PHASE IV CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
6. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY STUDY DESIGN, 2022 VS 2030 (%)
7. GLOBAL OBSERVATIONAL CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
8. GLOBAL INTERVENTIONAL CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
9. GLOBAL EXPANDED ACCESS CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
10. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET RESEARCH AND ANALYSIS BY INDICATION, 2022 VS 2030 (%)
11. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR CORONARY ARTERY DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
12. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR ACUTE CORONARY SYNDROME MARKET SHARE BY REGION, 2022 VS 2030 (%)
13. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR PULMONARY ARTERIAL HYPERTENSION MARKET SHARE BY REGION, 2022 VS 2030 (%)
14. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR ISCHEMIC HEART DISEASE MARKET SHARE BY REGION, 2022 VS 2030 (%)
15. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR STROKE MARKET SHARE BY REGION, 2022 VS 2030 (%)
16. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR HEART FAILURE MARKET SHARE BY REGION, 2022 VS 2030 (%)
17. GLOBAL CARDIOVASCULAR CLINICAL TRIALS FOR OTHER INDICATION MARKET SHARE BY REGION, 2022 VS 2030 (%)
18. GLOBAL CARDIOVASCULAR CLINICAL TRIALS MARKET SHARE BY REGION, 2022 VS 2030 (%)
19. US CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
20. CANADA CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
21. UK CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
22. FRANCE CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
23. GERMANY CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
24. ITALY CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
25. SPAIN CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
26. REST OF EUROPE CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
27. INDIA CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
28. CHINA CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
29. JAPAN CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
30. SOUTH KOREA CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
31. REST OF ASIA-PACIFIC CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
32. REST OF THE WORLD CARDIOVASCULAR CLINICAL TRIALS MARKET SIZE, 2022-2030 ($ MILLION)
